Nobutaka Hattori

Prof. Dr. Nobutaka Hattori

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2012 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KSKahori Shiba-Fukushima
Kahori Shiba-Fukushima
Yuzuru ImaiYuzuru Imai
Yuzuru Imai
SYShigeharu Yoshida
Shigeharu Yoshida
YIYasushi Ishihama
Yasushi Ishihama
TKTomoko Kanao
Tomoko Kanao
NHNobutaka Hattori
Nobutaka Hattori
Parkinson's disease genes PINK1 and parkin encode kinase and ubiquitin ligase, respectively. The gene products PINK1 and Parkin are implicated in mitochondrial autophagy, or mitophagy. Upon the loss of mitochondrial membrane potential (ΔΨm), cytosolic Parkin is recruited to the mitochondria by PINK1 through an uncharacterised mechanism – an initial step triggering sequential events in mitophagy. This study reports that Ser65 in the ubiquitin-like domain (Ubl) of Parkin is phosphorylated in a PINK1-dependent manner upon depolarisation of ΔΨm. The introduction of mutations at Ser65 suggests that phosphorylation of Ser65 is required not only for the efficient translocation of Parkin, but also for the degradation of mitochondrial proteins in mitophagy. Phosphorylation analysis of Parkin pathogenic mutants also suggests Ser65 phosphorylation is not sufficient for Parkin translocation. Our study partly uncovers the molecular mechanism underlying the PINK1-dependent mitochondrial translocation and activation of Parkin as an initial step of mitophagy.

1 February 2011 in Autophagy
Verified
Journal Article
Open access
SSShinji Saiki
Shinji Saiki
YSYukiko Sasazawa
Yukiko Sasazawa
YIYoko Imamichi
Yoko Imamichi
SKSumihiro Kawajiri
Sumihiro Kawajiri
TFTakahiro Fujimaki
Takahiro Fujimaki
NHNobutaka Hattori
Nobutaka Hattori
Caffeine is one of the most frequently ingested neuroactive compounds. All known mechanisms of apoptosis induced by caffeine act through cell cycle modulation or p53 induction. It is currently unkn...

6 October 2012 in Molecular Brain
Verified
Journal Article
Open access
PDF file
YIYoichi Imaizumi
Yoichi Imaizumi
YOYohei Okada
Yohei Okada
WAWado Akamatsu
Wado Akamatsu
MKMasato Koike
Masato Koike
NKNaoko Kuzumaki
Naoko Kuzumaki
Hideyuki OkanoHideyuki Okano
Hideyuki Okano
Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by selective degeneration of dopaminergic neurons in the substantia nigra (SN). The familial form of PD, PARK2, is caused by mutations in the parkin gene. parkin-knockout mouse models show some abnormalities, but they do not fully recapitulate the pathophysiology of human PARK2. Results: Here, we generated induced pluripotent stem cells (iPSCs) from two PARK2 patients. PARK2 iPSC-derived neurons showed increased oxidative stress and enhanced activity of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. iPSC-derived neurons, but not fibroblasts or iPSCs, exhibited abnormal mitochondrial morphology and impaired mitochondrial homeostasis. Although PARK2 patients rarely exhibit Lewy body (LB) formation with an accumulation of α-synuclein, α-synuclein accumulation was observed in the postmortem brain of one of the donor patients. This accumulation was also seen in the iPSC-derived neurons in the same patient. Conclusions: Thus, pathogenic changes in the brain of a PARK2 patient were recapitulated using iPSC technology. These novel findings reveal mechanistic insights into the onset of PARK2 and identify novel targets for drug screening and potential modified therapies for PD.

1 March 2015 in The Lancet Neurology
Verified
Journal Article
Closed access
MFManabu Funayama
Manabu Funayama
KOKenji Ohe
Kenji Ohe
TATaku Amo
Taku Amo
NFNorihiko Furuya
Norihiko Furuya
JYJunji Yamaguchi
Junji Yamaguchi
NHNobutaka Hattori
Nobutaka Hattori

29 May 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AOAyami Okuzumi
Ayami Okuzumi
THTaku Hatano
Taku Hatano
GMGen Matsumoto
Gen Matsumoto
SNShuko Nojiri
Shuko Nojiri
SUShinichi Ueno
Shinichi Ueno
NHNobutaka Hattori
Nobutaka Hattori
Abnormal α-synuclein aggregation is a key pathological feature of a group of neurodegenerative diseases known as synucleinopathies, which include Parkinson’s disease (PD), dementia with Lewy bodies and multiple system atrophy (MSA). The pathogenic β-sheet seed conformation of α-synuclein is found in various tissues, suggesting potential as a biomarker, but few studies have been able to reliably detect these seeds in serum samples. In this study, we developed a modified assay system, called immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC), which enables the detection of pathogenic α-synuclein seeds in the serum of individuals with synucleinopathies. In our internal first and second cohorts, IP/RT-QuIC showed high diagnostic performance for differentiating PD versus controls (area under the curve (AUC): 0.96 (95% confidence interval (CI) 0.95–0.99)/AUC: 0.93 (95% CI 0.84–1.00)) and MSA versus controls (AUC: 0.64 (95% CI 0.49–0.79)/AUC: 0.73 (95% CI 0.49–0.98)). IP/RT-QuIC also showed high diagnostic performance in differentiating individuals with PD (AUC: 0.86 (95% CI 0.74–0.99)) and MSA (AUC: 0.80 (95% CI 0.65–0.97)) from controls in a blinded external cohort. Notably, amplified seeds maintained disease-specific properties, allowing the differentiation of samples from individuals with PD versus MSA. In summary, here we present a novel platform that may allow the detection of individuals with synucleinopathies using serum samples.

6 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KYKazuo Yamashiro
Kazuo Yamashiro
RTRyota Tanaka
Ryota Tanaka
TUTakao Urabe
Takao Urabe
YUYuji Ueno
Yuji Ueno
YYYuichiro Yamashiro
Yuichiro Yamashiro
NHNobutaka Hattori
Nobutaka Hattori
The role of metabolic diseases in ischemic stroke has become a primary concern in both research and clinical practice. Increasing evidence suggests that dysbiosis is associated with metabolic diseases. The aim of this study was to investigate whether the gut microbiota, as well as concentrations of organic acids, the major products of dietary fiber fermentation by the gut microbiota, are altered in patients with ischemic stroke, and to examine the association between these changes and host metabolism and inflammation. We analyzed the composition of the fecal gut microbiota and the concentrations of fecal organic acids in 41 ischemic stroke patients and 40 control subjects via 16S and 23S rRNA-targeted quantitative reverse transcription (qRT)-PCR and high-performance liquid chromatography analyses, respectively. Multivariable linear regression analysis was subsequently performed to evaluate the relationships between ischemic stroke and bacterial counts and organic acid concentrations. Correlations between bioclinical markers and bacterial counts and organic acids concentrations were also evaluated. Although only the bacterial counts of Lactobacillus ruminis were significantly higher in stroke patients compared to controls, multivariable analysis showed that ischemic stroke was independently associated with increased bacterial counts of Atopobium cluster and Lactobacillus ruminis, and decreased numbers of Lactobacillus sakei subgroup, independent of age, hypertension, and type 2 diabetes. Changes in the prevalence of Lactobacillus ruminis were positively correlated with serum interleukin-6 levels. In addition, ischemic stroke was associated with decreased and increased concentrations of acetic acid and valeric acid, respectively. Meanwhile, changes in acetic acid concentrations were negatively correlated with the levels of glycated hemoglobin and low-density lipoprotein cholesterol, whereas changes in valeric acid concentrations were positively correlated with the level of high sensitivity C-reactive protein and with white blood cell counts. Together, our findings suggest that gut dysbiosis in patients with ischemic stroke is associated with host metabolism and inflammation.